| Title: |
Methods and Compositions Related to Immunizing Against Staphylococcal Lung Diseases and Conditions |
| Document Number: |
20110027265 |
| Publication Date: |
February 3, 2011 |
| Appl. No: |
12/675597 |
| Application Filed: |
August 29, 2008 |
| Abstract: |
Embodiments of the invention include methods and compositions useful in a vaccination strategy capable of neutralizing HIa to provide immunoprotection against S. aureus pneumonia. In certain aspects the invention includes a HIa with reduced toxicity, represented by a recombinant mutant form of HIa (HlaH35L) in which histidine 35 is converted to leucine, which can be used to abrogate the productive assembly of the toxin and protect a subject from staphylococcal pneumonia. |
| Inventors: |
Bubeck-Wardenburg, Juliane (Frankfort, IL, US); Schneewind, Olaf (Chicago, IL, US); Ragle, Brook (Chicago, IL, US) |
| Assignees: |
The University of Chicago (Chicago, IL, US) |
| Claim: |
1. A method of eliciting an immune response in a patient to a staphylococcal bacteria comprising administering to a patient an effective amount of a composition comprising a purified recombinant and attenuated Staphylococcus α-hemolysin (Hla) toxin, wherein the composition contains no more than contaminating amounts of any other Staphylococcus protein. |
| Claim: |
2. (canceled) |
| Claim: |
3. The method of claim 1, wherein the patient is hospitalized or will be hospitalized; or the patient will undergo surgery and/or be anesthetized. |
| Claim: |
4. (canceled) |
| Claim: |
5. (canceled) |
| Claim: |
6. The method of claim 1, wherein the attenuated Hla toxin lacks detectable hemolytic activity and/or the attenuated Hla toxin lacks detectable lethal activity. |
| Claim: |
7. (canceled) |
| Claim: |
8. The method of claim 1, wherein the Hla toxin has a leucine substituted for a histidine at amino acid 35. |
| Claim: |
9. The method of claim 1, wherein the Hla toxin is not substantially denatured. |
| Claim: |
10. (canceled) |
| Claim: |
11. The method of claim 1, wherein the Hla toxin comprises no more than amino acids 1-50 of mature Hla toxin. |
| Claim: |
12. The method of claim 1, further comprising testing the patient for antibodies against Hla toxin. |
| Claim: |
13. The method of claim 1, wherein the patient is administered the composition multiple times. |
| Claim: |
14. The method of claim 1, wherein the composition further comprises at least one adjuvant. |
| Claim: |
15. The method of claim 14, wherein the adjuvant is conjugated to the Hla toxin. |
| Claim: |
16. The method of claim 1, wherein the composition is administered mucosally, intramuscularly, intransally, or is inhaled. |
| Claim: |
17. (canceled) |
| Claim: |
18. The method of claim 1, wherein the staphylococcal lung disease or condition is pneumonia. |
| Claim: |
19. A method for preventing a staphylococcal lung disease or condition in a patient comprising: administering to the patient an effective amount of a composition comprising recombinant and attenuated Staphylococcus α-hemolysin (Hla) toxin, wherein the composition does not elicit a detectable immune response against any other Staphylococcus protein. |
| Claim: |
20.-54. (canceled) |
| Claim: |
55. A method of protecting a patient from a staphylococcal lung disease or condition, or treating a patient with a staphylococcal lung disease or condition comprising administering to the patient an effective amount of a composition including antibodies that are immunologically reactive against Staphylococcus aureus α-hemolysin (Hla). |
| Claim: |
56. The method of claim 55, wherein the antibodies are humanized antibodies. |
| Claim: |
57. The method of claim 55, wherein the antibodies are human antibodies. |
| Claim: |
58. The method of claim 55, wherein the antibodies are monoclonal antibodies or are immunological portions of an antibody. |
| Claim: |
59. (canceled) |
| Claim: |
60. The method of claim 55, wherein the patient is hospitalized or will be hospitalized; or the patient will undergo surgery and/or be anesthetized. |
| Claim: |
61.-64. (canceled) |
| Claim: |
65. The method of claim 55, wherein the composition is administered intravenously. |
| Claim: |
66. (canceled) |
| Claim: |
67. The method of claim 55, wherein the staphylococcal lung disease or condition is pneumonia. |
| Claim: |
68.-76. (canceled) |
| Current U.S. Class: |
4241/331 |
| Current International Class: |
61; 61; 61; 61 |
| Accession Number: |
edspap.20110027265 |
| Database: |
USPTO Patent Applications |
